vs

Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and PEDEVCO CORP (PED). Click either name above to swap in a different company.

PEDEVCO CORP is the larger business by last-quarter revenue ($23.1M vs $20.0M, roughly 1.2× AGIOS PHARMACEUTICALS, INC.). PEDEVCO CORP runs the higher net margin — -36.8% vs -541.1%, a 504.3% gap on every dollar of revenue. On growth, PEDEVCO CORP posted the faster year-over-year revenue change (118.2% vs 86.1%). Over the past eight quarters, PEDEVCO CORP's revenue compounded faster (68.6% CAGR vs 56.1%).

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.

PEDEVCO Corp is an independent energy company specializing in the acquisition, exploration, development, and production of oil and natural gas assets. It primarily holds and operates onshore resource properties across continental US basins, serving domestic wholesale, utility, and industrial energy customer segments.

AGIO vs PED — Head-to-Head

Bigger by revenue
PED
PED
1.2× larger
PED
$23.1M
$20.0M
AGIO
Growing faster (revenue YoY)
PED
PED
+32.2% gap
PED
118.2%
86.1%
AGIO
Higher net margin
PED
PED
504.3% more per $
PED
-36.8%
-541.1%
AGIO
Faster 2-yr revenue CAGR
PED
PED
Annualised
PED
68.6%
56.1%
AGIO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AGIO
AGIO
PED
PED
Revenue
$20.0M
$23.1M
Net Profit
$-108.0M
$-8.5M
Gross Margin
90.6%
Operating Margin
-608.9%
-21.3%
Net Margin
-541.1%
-36.8%
Revenue YoY
86.1%
118.2%
Net Profit YoY
-11.9%
-243.5%
EPS (diluted)
$-1.86
$-2.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AGIO
AGIO
PED
PED
Q4 25
$20.0M
$23.1M
Q3 25
$12.9M
$7.0M
Q2 25
$12.5M
$7.0M
Q1 25
$8.7M
$8.7M
Q4 24
$10.7M
$10.6M
Q3 24
$9.0M
$9.1M
Q2 24
$8.6M
$11.8M
Q1 24
$8.2M
$8.1M
Net Profit
AGIO
AGIO
PED
PED
Q4 25
$-108.0M
$-8.5M
Q3 25
$-103.4M
$-325.0K
Q2 25
$-112.0M
$-1.7M
Q1 25
$-89.3M
$140.0K
Q4 24
$-96.5M
$5.9M
Q3 24
$947.9M
$2.9M
Q2 24
$-96.1M
$2.7M
Q1 24
$-81.5M
$773.0K
Gross Margin
AGIO
AGIO
PED
PED
Q4 25
90.6%
Q3 25
87.0%
Q2 25
86.3%
Q1 25
87.6%
Q4 24
88.3%
Q3 24
91.3%
Q2 24
82.6%
Q1 24
92.3%
Operating Margin
AGIO
AGIO
PED
PED
Q4 25
-608.9%
-21.3%
Q3 25
-907.4%
-12.0%
Q2 25
-1020.1%
-32.2%
Q1 25
-1222.0%
1.7%
Q4 24
-1165.3%
-12.9%
Q3 24
-1146.9%
31.3%
Q2 24
-1228.3%
22.3%
Q1 24
-1124.3%
7.6%
Net Margin
AGIO
AGIO
PED
PED
Q4 25
-541.1%
-36.8%
Q3 25
-803.1%
-4.7%
Q2 25
-899.4%
-24.0%
Q1 25
-1023.3%
1.6%
Q4 24
-899.6%
56.0%
Q3 24
10574.7%
32.2%
Q2 24
-1115.7%
22.7%
Q1 24
-995.8%
9.5%
EPS (diluted)
AGIO
AGIO
PED
PED
Q4 25
$-1.86
$-2.23
Q3 25
$-1.78
$0.00
Q2 25
$-1.93
$-0.02
Q1 25
$-1.55
$0.00
Q4 24
$-1.44
$2.69
Q3 24
$16.22
$0.03
Q2 24
$-1.69
$0.03
Q1 24
$-1.45
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AGIO
AGIO
PED
PED
Cash + ST InvestmentsLiquidity on hand
$89.1M
$3.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.2B
$207.4M
Total Assets
$1.3B
$375.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AGIO
AGIO
PED
PED
Q4 25
$89.1M
$3.2M
Q3 25
$92.7M
$10.9M
Q2 25
$80.9M
$8.5M
Q1 25
$79.0M
$10.4M
Q4 24
$76.2M
$4.0M
Q3 24
$253.7M
$4.6M
Q2 24
$84.5M
$6.1M
Q1 24
$118.8M
$13.3M
Stockholders' Equity
AGIO
AGIO
PED
PED
Q4 25
$1.2B
$207.4M
Q3 25
$1.3B
$115.4M
Q2 25
$1.4B
$115.2M
Q1 25
$1.5B
$116.2M
Q4 24
$1.5B
$115.6M
Q3 24
$1.6B
$106.5M
Q2 24
$660.5M
$103.2M
Q1 24
$743.9M
$100.0M
Total Assets
AGIO
AGIO
PED
PED
Q4 25
$1.3B
$375.9M
Q3 25
$1.4B
$135.9M
Q2 25
$1.5B
$136.8M
Q1 25
$1.6B
$145.6M
Q4 24
$1.7B
$128.3M
Q3 24
$1.8B
$114.3M
Q2 24
$773.1M
$111.0M
Q1 24
$849.7M
$118.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AGIO
AGIO
PED
PED
Operating Cash FlowLast quarter
$-96.2M
$-2.1M
Free Cash FlowOCF − Capex
$-97.3M
FCF MarginFCF / Revenue
-487.5%
Capex IntensityCapex / Revenue
5.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-377.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AGIO
AGIO
PED
PED
Q4 25
$-96.2M
$-2.1M
Q3 25
$-88.2M
$7.4M
Q2 25
$-77.1M
$-420.0K
Q1 25
$-111.5M
$5.9M
Q4 24
$-133.2M
$4.2M
Q3 24
$-84.2M
$8.3M
Q2 24
$-72.6M
$4.6M
Q1 24
$-99.9M
$-4.3M
Free Cash Flow
AGIO
AGIO
PED
PED
Q4 25
$-97.3M
Q3 25
$-89.7M
Q2 25
$-78.0M
Q1 25
$-112.3M
Q4 24
$-134.1M
Q3 24
$-84.6M
Q2 24
$-72.7M
Q1 24
$-100.0M
FCF Margin
AGIO
AGIO
PED
PED
Q4 25
-487.5%
Q3 25
-696.5%
Q2 25
-626.2%
Q1 25
-1286.4%
Q4 24
-1250.1%
Q3 24
-944.2%
Q2 24
-844.4%
Q1 24
-1221.2%
Capex Intensity
AGIO
AGIO
PED
PED
Q4 25
5.6%
Q3 25
12.1%
Q2 25
7.0%
Q1 25
8.8%
Q4 24
9.0%
Q3 24
4.7%
Q2 24
1.8%
Q1 24
1.7%
Cash Conversion
AGIO
AGIO
PED
PED
Q4 25
Q3 25
Q2 25
Q1 25
42.34×
Q4 24
0.71×
Q3 24
-0.09×
2.83×
Q2 24
1.71×
Q1 24
-5.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons